Futures
Hundreds of contracts settled in USDT or BTC
TradFi
Gold
Trade global traditional assets with USDT in one place
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Participate in events to win generous rewards
Demo Trading
Use virtual funds to experience risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and enjoy airdrop rewards!
Futures Points
Earn futures points and claim airdrop rewards
Investment
Simple Earn
Earn interests with idle tokens
Auto-Invest
Auto-invest on a regular basis
Dual Investment
Buy low and sell high to take profits from price fluctuations
Soft Staking
Earn rewards with flexible staking
Crypto Loan
0 Fees
Pledge one crypto to borrow another
Lending Center
One-stop lending hub
VIP Wealth Hub
Customized wealth management empowers your assets growth
Private Wealth Management
Customized asset management to grow your digital assets
Quant Fund
Top asset management team helps you profit without hassle
Staking
Stake cryptos to earn in PoS products
Smart Leverage
New
No forced liquidation before maturity, worry-free leveraged gains
GUSD Minting
Use USDT/USDC to mint GUSD for treasury-level yields
Shawn Leland Takes Helm as Affimed's Chief Executive Officer
Immuno-oncology-focused Affimed N.V. (AFMD) has revealed a significant leadership transition, with Shawn Leland now stepping into the role of Chief Executive Officer. This appointment marks a strategic move for the company as it charts its next phase of development.
Leland brings substantial industry credentials to the position, boasting over 15 years of progressive experience in pharmaceutical and biotechnology sectors. His career trajectory demonstrates a consistent pattern of scaling companies through critical growth phases. Prior to joining Affimed, Leland served as Interim CEO and Board Director at ForeBio, where he provided interim leadership and strategic direction.
The incoming CEO’s entrepreneurial background is particularly noteworthy. In 2019, Leland founded Elevation Oncology, initially taking the Chief Business Officer seat before advancing to the Chief Executive role through January 2023. Before establishing his own venture, Leland honed his business development expertise at Verastem Oncology (2017-2019) and spent four years as Head of Business Development at Argos Therapeutics (2013-2017).
His early career foundation was built at established pharma powerhouses including ARIAD Pharmaceuticals and Eli Lilly, where he gained hands-on experience navigating the complexities of drug development and market strategy.
Meanwhile, Andreas Harstrick, who has been steering Affimed as acting CEO since January 2024, will transition to his role as Chief Medical Officer. This structural change allows the company to benefit from both Leland’s business acumen and Harstrick’s medical expertise as they work in complementary capacities.